引发下跌的主要原因在于全球减肥药市场日益激烈的竞争，以及诺和诺德本身的供应限制，降低了市场对该公司减肥药业务的追捧。① Danish pharmaceutical company Novo Nordisk's stock price fell more than 40% from the year's high due to increased competition in the diet pills market, supply restrictions and lower than expected financial reports; ② Novo Nordisk's financial director acknowledged that next year's sales growth rate may be 10%, far behind market expectations; ③ Analysts believe that the current sell-off sentiment on diet pills is excessive, and the company still has high investment value.
Financial Services, November 21 (Editor Malan) Danish pharmaceutical company Novo Nordisk previously ushered in the peak of business development due to diet pills, but it also became the target of market doubts due to diet pills.
The stock's current stock price has fallen back to close to the level at the beginning of the year, basically erasing the increase brought about by diet pills at the beginning of the year, down more than 40% from its high during the year.
The main reason for the decline was increasingly fierce competition in the global diet pills market, as well as Novo Nordisk's own supply restrictions, which reduced the market's demand for the company's diet medicine business.
Novo Nordisk's earnings report released earlier this month also amplified this concern. Its financial director Karsten Munk Knudsen acknowledged that next year's sales growth rate could be 10%, falling far short of market expectations.
Barclays Bank said earlier that Novo Nordisk's outlook for 2025 is putting pressure on the share price.
Still optimistic
As soon as Novo Nordisk's flagship products Ozempic and Wegovy were launched, they were insanely sought after by weight loss people. As a result, the company's stock price repeatedly broke new highs and quickly became the largest company in Europe by market capitalization. As of now, Novo Nordisk is still the largest listed company in Europe, with a market capitalization of $358 billion.
However, as competitor Eli Lilly drastically expanded its weight loss drug production capacity this year, this had an impact on Novo Nordisk's market share.
Meanwhile, Trump's appointment of “anti-vaccine fighter” Robert Kennedy Jr., as US Secretary of Health and Human Services may also have a negative impact on diet medicine companies. Kennedy has always been critical of weight loss drugs, and some investors believe he will change the pricing or health insurance coverage of weight loss drugs, thereby weakening the profit prospects of diet pills.
However, some analysts pointed out that the current sell-off sentiment on diet pills is excessive, and Novo Nordisk still has a high investment value. Currently, analysts' target 12-month share price for the stock is still close to its all-time high.
Gilles Guibout, head of European stock strategy at AXA Investments in Paris, said that Novo Nordisk's stock price speculation this year was too intense, and the current sharp fluctuations may be due to the behavior of hedge funds. He stressed that Novo Nordisk shares are widely held and the market potential is huge, so there are always more sellers than buyers, and it is also easy to form a downward trend.
In December, Novo Nordisk will release data on its latest next-generation diet drug Cagrisema, and investors are waiting for it.
